Utility of aquaporin-4 antibody assay in patients with neuromyelitis optica spectrum disorders

Abstract

Objective:

Our aim was to evaluate the utility of aquaporin-4 antibodies (AQP4-Ab) in patients with neuromyelitis optica spectrum disorders (NMOSD).

Methods:

The clinical and radiological characteristics of 78 patients with NMOSD and 22 with multiple sclerosis (MS), who were tested for AQP4-Ab by a cell-based assay, were assessed.

Results:

The mean time interval between symptom onset and development of optic neuritis and myelitis was 39.9 months in neuromyelitis optica (NMO). About 40% of patients with limited NMO would have fulfilled the diagnostic criteria for MS in the absence of the antibody assay results. In patients with longitudinally extensive transverse myelitis, positive AQP4-Ab assay results were associated with the poor response to acute steroid treatment and asymptomatic visual evoked potential abnormality. Presence of either painful tonic spasm associated with myelitis or severe disability at onset had high specificity and relatively high sensitivity in differentiating NMOSD with AQP4-Ab from MS.

Conclusions:

The AQP4-Ab assay can facilitate the early diagnosis of NMO and prevent limited NMO from being misdiagnosed as MS. It can predict the poor response to first-line acute-phase treatment and probably detect the subclinical optic nerve involvement in subgroups of NMOSD. Lastly, it will contribute to the upcoming revision of the current diagnostic criteria for NMO.

Keywords

Neuromyelitis optica multiple sclerosis anti-aquaporin-4 antibody

Get full access to this article

View all access options for this article.

References

Wingerchuk

Lennon

Pittock

. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66: 1485–1489.

Kim

New insights into neuromyelitis optica. J Clin Neurol 2011; 7: 115–127.

Siritho

Nakashima

Takahashi

. AQP4 antibody-positive Thai cases: Clinical features and diagnostic problems. Neurology 2011; 77: 827–834.

Weinshenker

Carroll

Does detection of anti-AQP4 antibodies trump clinical criteria for neuromyelitis optica?

Neurology 2011; 77: 812–813.

Wingerchuk

Lennon

Lucchinetti

. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815.

Canellas

Gols

Izquierdo

. Idiopathic inflammatory-demyelinating diseases of the central nervous system. Neuroradiology 2007; 49: 393–409.

Trebst

Raab

Voss

. Longitudinal extensive transverse myelitis – it’s not all neuromyelitis optica. Nat Rev Neurol 2011; 7: 688–698.

McClelland

Van Stavern

Tselis

Leber hereditary optic neuropathy mimicking neuromyelitis optica. J Neuroophthalmol 2011; 31: 265–268.

Kitley

Leite

George

. The differential diagnosis of longitudinally extensive transverse myelitis. Mult Scler 2012; 18: 271–285.

10.

Kruer

Koch

Bourdette

. NMDA receptor encephalitis mimicking seronegative neuromyelitis optica. Neurology 2010; 74: 1473–1475.

11.

Jarius

Frederikson

Waters

. Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158–162.

12.

Matiello

Lennon

Jacob

. NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 2008; 70: 2197–2200.

13.

Polman

Reingold

Banwell

. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011; 69: 292–302.

14.

Kim

Sung

. Painful tonic spasm in neuromyelitis optica: Incidence, diagnostic utility, and clinical characteristics. Arch Neurol 2012; 69: 1026–1031.

15.

Kim

Waters

Vincent

. Cerebrospinal fluid/serum gradient of IgG is associated with disability at acute attacks of neuromyelitis optica. Journal of neurology 2011.

16.

Teunissen

Petzold

Bennett

. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology 2009; 73: 1914–1922.

17.

Waters

Jarius

Littleton

. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65: 913–919.

18.

Kurtzke

Rating neurologic impairment in multiple sclerosis: An Expanded Disability Status Scale (EDSS). Neurology 1983; 33: 1444–1452.

19.

Weinshenker

O’Brien

Petterson

. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878–886.

20.

Odom

Bach

Brigell

. ISCEV standard for clinical visual evoked potentials (2009 update). Doc Ophthalmol 2010; 120: 111–119.

21.

Kim

Waters

Vincent

. Sjogren’s syndrome myelopathy: Spinal cord involvement in Sjogren’s syndrome might be a manifestation of neuromyelitis optica. Mult Scler 2009; 15: 1062–1068.

22.

Bradl

Misu

Takahashi

. Neuromyelitis optica: Pathogenicity of patient immunoglobulin in vivo. Ann Neurol 2009; 66: 630–643.

23.

Collongues

Marignier

Zephir

. High-risk syndrome for neuromyelitis optica: A descriptive and comparative study. Mult Scler 2011; 17: 720–724.

24.

Palace

Leite

Nairne

. Interferon beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 2010; 67: 1016–1017.

25.

Kleiter

Hellwig

Berthele

. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 2012; 69: 239–245.

26.

Barnett

Prineas

Buckland

. Massive astrocyte destruction in neuromyelitis optica despite natalizumab therapy. Mult Scler 2012; 18: 108–112.

27.

Hachinski

Potter

Merskey

Leuko-araiosis. Arch Neurol 1987; 44: 21–23.

28.

Green

Cree

Distinctive retinal nerve fibre layer and vascular changes in neuromyelitis optica following optic neuritis. J Neurol Neurosurg Psychiatry 2009; 80: 1002–1005.

29.

Kim

Vincent

. Clinical characteristics, prognosis, and seropositivity to the anti-aquaporin-4 antibody in Korean patients with longitudinally extensive transverse myelitis. J Neurol 2010; 257: 920–925.

30.

Weinshenker

Wingerchuk

Vukusic

. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59: 566–569.

31.

Wang

Tsai

Lee

. The prevalence of long spinal cord lesions and anti-aquaporin 4 antibodies in neuromyelitis optica patients in Taiwan. Eur Neurol 2011; 65: 99–104.

32.

Trebst

Raab

Voss

. Longitudinal extensive transverse myelitis – it’s not all neuromyelitis optica. Nat Rev Neurol 2011; 7: 688–698.

33.

Uzawa

Mori

Muto

. When is neuromyelitis optica diagnosed after disease onset? J Neurol 2012; 259: 1066–1605.

34.

Kira

Multiple sclerosis in the Japanese population. Lancet Neurol 2003; 2: 117–127.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.04 MB